Full access to Entrepreneur for $5
Subscribe

Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies

Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.

By
This story originally appeared on Zacks

Celsion Corporation CLSN announced that its next generation PLACCINE DNA vaccine platform demonstrated potential in pre-clinical in-vivostudies against COVID-19.

- Zacks

Data from the study that evaluated the vaccine platform in BALB/c mice demonstrated production of antibodies and cytotoxic T-cell response specific to the spike antigen of COVID-19. These antibodies prevented the infection of cultured cells in a viral neutralization assay.

Shares of Celsion gained 2.9% following the above-mentioned news. In fact, the stock has rallied 49.1% so far this year in comparison with the industry’s 2% growth.

Zacks Investment Research

Image Source: Zacks Investment Research

We inform investors that PLACCINE is the company’s proprietary plasmid and DNA delivery technology that covers a wide range of DNA vaccines. While the production of antibodies predicts PLACCINE’s ability to protect against COVID-19, the induction of cytotoxic T-cell response shows the vaccine’s potential of eradicating COVID-infected cells.

Celsion targets to file an investigational new drug for the candidate in early-2022, after it conducts further studies with the goal of optimizing PLACCINE DNA vaccine activity in terms of vector design, dosage and delivery.

Per the company, the platform incorporates multiple viral antigens to improve vaccine quality, and facilitates cheaper and easier manufacturing. The platform also aims at improving vaccine stability at storage temperatures of 4°C and above. Celsion is also developing the vaccine to be administered intramuscularly based on a specialized synthetic delivery system that yields high levels of viral proteins to generate the desired immune response.

Last week, Sorrento SRNE also announced positive initial data from pre-clinical study for its mRNA vaccine, STI-mRNA, against the COVID-19 pandemic. The vaccine comprises proprietary designer Spike-encoding mRNAs, with the potential of improving durability for both humoral and cellular immunity against the current and emerging variants of COVID-19.

Pfizer PFE/BioNTech’s BNTX mRNA vaccine, Comirnaty became the first FDA-approved vaccine to receive full approval.

Zacks Rank

Celsion presently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.



Tech IPOs With Massive Profit Potential: Last years top IPOs surged as much as 299% within the first two months. With record amounts of cash flooding into IPOs and a record-setting stock market, this year could be even more lucrative. 

See Zacks’ Hottest Tech IPOs Now >>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Pfizer Inc. (PFE): Free Stock Analysis Report

 

Celsion Corporation (CLSN): Free Stock Analysis Report

 

Sorrento Therapeutics, Inc. (SRNE): Free Stock Analysis Report

 

BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research